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Abbreviations 
AB   aberrant body 
BAL   bronchoalveolar lavage  
bp   base pair 
C. muridarum Chlamydia muridarum 
C. pneumoniae Chlamydophila pneumoniae 
C. trachomatis Chlamydia trachomatis 
DC   dendritic cell 
EB   elementary body 
ELISA   enzyme-linked immunosorbent assay  
FITC    fluorescein isothiocyanate 
GM-CSF  granulocyte-macrophage colony-stimulating factor 
i.p.    intraperitoneal 
IFN-γ   interferon-γ 
IFU    inclusion forming unit  
Ig   immunoglobulin 
IL   interleukin 
KC    keratinocyte chemoattractant 
kDa   kilodalton 
LC-MS/MS   liquid chromatography-tandem mass spectrometry 
LIX    lipopolysaccharide-induced C-X-C chemokine  
LPS   lipopolysaccharide 
MIG    monokine induced by IFN-γ  
MIP-2   macrophage inflammatory protein-2 
MW   molecular weight 
NK    natural killer  
ORF    open reading frame 
PBS    phosphate-buffered saline  
pMoPn   the plasmid of C. muridarum 
PRR   pattern recognition receptors  
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RB    reticulate body 
rRNA   ribosomal RNA 
RT qPCR   quantitative reverse transcription polymerase chain reaction  
SD   standard deviation 
SFCs    spot-forming cells  
SI   stimulation index 
SPG    sucrose-phosphate-glutamic acid buffer   
Th   T helper 
TLR   Toll-like receptor 
TNF-α   tumour necrosis factor-α 
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Introduction 
 
Chlamydiae cause infections that are common throughout the world. Although antibiotics 
are effective in treating chlamydial infections, the lack of obvious symptoms has the 
consequence that many infections remain untreated potentially leading to complications 
characterised by inflammatory pathologies. The immunity to these pathogens is not effective, 
chlamydial infections display high rates of recurrence and have long-term consequences 
causing a serious public health problem. Immunisation is a desirable approach for the 
prevention and control of chlamydial disease, but despite considerable efforts there is 
currently no commercially available vaccine against chlamydiae. Understanding the basis of 
immunity to chlamydiae will provide an indispensable knowledge for the design of a vaccine 
against diseases caused by chlamydiae. The present study was designated to improve our 
current understanding of the pathological immune response to infection and re-infection with 
chlamydiae, and to provide information about the host immune responses against the different 
chlamydial plasmid proteins.  
 
Chlamydiaceae 
Chlamydiaceae is a family of Gram negative, obligate intracellular bacteria responsible 
for a wide range of diseases with clinical and public health importance. Based on the 16S and 
23S ribosomal gene sequences the Chlamydiaceae is divided into two genera: Chlamydophila 
and Chlamydia. The genus Chlamydophila is composed of six species: Chlamydophila 
pneumoniae; Chlamydophila psittaci; Chlamydophila pecorum; Chlamydophila abortus; 
Chlamydophila caviae and Chlamydophila felis. Three species belong in the Chlamydia 
genus: the human pathogen Chlamydia trachomatis; the mouse adapted Chlamydia 
muridarum and Chlamydia suis, which infects swine
1
.  
Chlamydiae undergo a unique biphasic developmental cycle, during which the bacterium 
is found in two forms, the extracellular form, called elementary body (EB), which is 
metabolically inert and infectious, and the intracellular form, the reticulate body (RB), which 
is metabolically active, replicative but non-infectious. The chlamydial developmental cycle is 
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divided into five major steps: the infectious EB attaches to and enters the host cell resulting in 
the formation of an inclusion, which creates a permissive intracellular niche for replication; 
EB differentiates into RB; RB replicates by binary fission; increasing numbers of RBs 
differentiate back to EBs; the newly formed EBs are released by lysis or extrusion from the 
host cell allowing infection of neighbouring cells (Fig. 1). The duration of the developmental 
cycle is 48-72 hours depending on the chlamydia species
2
. Over the past years increasing 
number of studies suggest that considering the chlamydial developmental cycle a biphasic 
process may underestimate its complexity. Under stress chlamydiae can enter a dormant, non-
infectious but viable state named persistence, during which they exist in an enlarged aberrant 
body (AB). Several different stimuli can induce persistence of chlamydiae in vitro: exposure 
to interferon-γ (IFN-γ) and antibiotics; heat shock; depletion of essential nutrients. Persistence 
is reversible, after the inducer is removed chlamydiae continue their productive replication
3
. 
Experimental and clinical data provide evidence for reactivation of persistent chlamydiae in 
vivo indicating that chlamydial recurrences were more likely due to the reactivations of 
persistent infections than to re-infections
4
. 
 
 
Fig. 1 General overview of the chlamydial developmental cycle
3
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Chlamydophila pneumoniae 
C. pneumoniae is a common and important respiratory tract pathogen; it causes about 
10% of community-acquired pneumonia in adults and 5% of bronchitis and sinusitis. 
However, due to the lack of obvious symptoms most of the infections caused by C. 
pneumoniae remain undiagnosed. Seroepidemiological studies shows that 75% of the 
population became infected with C. pneumoniae before the age of 20 and re-infection during 
their lifetime was very common
5
. Most of the studies regarding C. pneumoniae focus on its 
role as a cause of persistent infections in chronic diseases. The association of C. pneumoniae 
with chronic diseases was first published in 1988, when Saikku et al. revealed the role of C. 
pneumoniae in chronic coronary heart disease and acute myocardial infarction
6
. Thenceforth a 
number of studies supported the role of C. pneumoniae infections in chronic human diseases 
such as chronic bronchitis, asthma, atherosclerosis, Alzheimer’s disease, reactive arthritis and 
lung cancer 
7–11
.  
Similar to other bacteria, C. pneumoniae infections initiate the innate immune response of 
the host by recognition of the pathogen via pattern recognition receptors (PRRs). Toll-like 
receptors (TLRs) are one of the most important family of PRRs, which are expressed on 
epithelial cells, neutrophils, macrophages and dendritic cells (DCs)
12
. Moreover, the 
recognition of cell wall components or heat shock proteins by TLR2 appears to be essential 
for development of the inflammatory response to infection with C. pneumoniae
13
. Activation 
of the TLRs initiates downstream signalling, which induces transcription factors and the 
expression of inflammatory and immune response-related genes resulting in a localised 
inflammation largely mediated by polymorphonuclear and mononuclear leukocytes, which are 
recruited by different cytokines and chemokines
14
. Infection with C. pneumoniae triggers the 
production of a wide range of chemokines, including the monokine induced by IFN-γ (MIG); 
the IFN-γ-inducible protein of 10 kDa and the IFN-inducible T cell alpha chemoattractant. 
Besides the recruiting role of the chemokines, some of them act like defensins and possess 
antimicrobial activity
15
. It was earlier revealed that MIG had a dose dependent antichlamydial 
effect in vitro
16
. Thus, the MIG, which is released by non-immune cells, could directly 
inactivate C. pneumoniae, while also assisting the recruitment of neutrophils to the infected 
tissue.  
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Innate immune responses can also induce the adaptive immunity and acquired 
immunological memory. Antigen presenting cells activate naive T lymphocytes by presenting 
chlamydia-specific antigens. Those T lymphocytes, which are bearing a chlamydia-specific T 
cell receptor undergo clonal expansion and mediate effector functions
17
. According to a 
classical paradigm CD4
+
 T cells are assigned to either T helper (Th) 1 or Th2 subset based on 
the cytokines secreted by them. Th1 cells produce IFN-γ and are regulated by interleukin (IL)-
12, while Th2 cells produce the cytokines IL-4, IL-5, and IL-13
18
. Th1 cells regulate cellular 
immune response and are associated with protection against intracellular pathogens; Th2 cells 
play crucial roles in humoral immunity, and are involved in the defence against extracellular 
bacteria
19
. A murine study has recently demonstrated that the influx of activated Th1 cells and 
the effective release of IFN-γ are critical for the defence against C. pneumoniae20. 
The evidence of the participation of C. pneumoniae infections in chronic inflammatory 
disease comes from the fact that the primary infection elicits some protective immunity 
against re-infection, but provides no protection against inflammatory changes which may lead 
to irreversible tissue damage. Moreover, in the case of persistent infection, although C. 
pneumoniae is in a dormant state, but the 60 kDa heat shock protein is expressed and the 
release of chlamydial antigens from infected cells may provide a prolonged antigenic 
stimulation, which amplifies the chronic inflammation
21
. Studies published recently focus on 
the role of C. pneumoniae infection in allergic airway inflammation. In asthma patients the 
airway hyperresponsiveness is mainly characterised by the infiltration of neutrophils, which is 
also typical for respiratory tract infection with C. pneumoniae
22
. The mechanism, by which C. 
pneumoniae induces the influx of neutrophil granulocytes to the lung tissue and elicits allergic 
immune response in persistent infections or re-infections remains poorly understood.  
 
Th17 cells and IL-17 cytokine family  
During the last decade, researchers investigating chronic inflammatory diseases focused 
their attention on a newly identified subset of CD4
+
 lymphocytes named Th17 cells, and the 
members of the IL-17 cytokine family also became a prominent subject for investigation. 
Recent progress in studies revealed important roles for Th17 cells in the development of 
allergic and autoimmune diseases, and in protective mechanisms against bacterial and fungal 
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infections, functions previously believed to be mediated by Th1 or Th2 cells. Th17 cells 
produce IL-17A, IL-17F, IL-21 and IL-22
23
. Th17 cell differentiation from naive CD4
+
 T 
cells is controlled by transforming growth factor- IL-6 and IL-21, however IL-1 and IL-23 
are critical for survival and effector functions of Th17 cells
24
. IL-23 promotes the 
development and expansion of activated CD4
+
 T cells that produce IL-17A upon antigen-
specific stimulation
25
.  
The IL-17 cytokine family consists of six members designated as IL-17A, IL-17B, IL-
17C, IL-17D, IL-17E (also called IL-25) and IL-17F (Table 1). Th17 cells are the main 
source of IL-17A and IL-17F, but CD8
+
 cells, γδ T cells and natural killer (NK) cells can also 
produce these cytokines. IL-17A and IL-17F share the strongest homology, they bind to the 
same receptor, which suggests that they exhibit similar biological activities. Both IL-17A and 
IL-17F induce expression of genes encoding pro-inflammatory cytokines and chemokines 
such as keratinocyte chemoattractant (KC), lipopolysaccharide (LPS)-induced C-X-C 
chemokine (LIX), and macrophage inflammatory protein-2 (MIP-2) in fibroblasts, endothelial 
and epithelial cells. IL-17A plays a crucial role in innate immune response against pathogens 
by promoting granulocyte-macrophage colony-stimulating factor (GM-CSF) mediated 
granulopoiesis and recruiting neutrophils to the sites of inflammation
26,27
. Besides combating 
microbial infections, a most prominent function associated with IL-17A is the regulation of 
autoimmunity, and dysregulation of Th17 cells leads to severe disease such as multiple 
sclerosis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease and 
psoriasis
28–32
. In addition, numerous studies suggest pathological role of IL-17A in allergic 
responses and in promotion of disease progression in atopic dermatitis and asthma. Although, 
the exact function of Th17 cells in the development of asthma remains to be elucidated. The 
functions of IL-17B, IL-17C and IL-17D are largely elusive.  
IL17E, also known as IL-25 appears to be involved in Th2 immune response and in host 
defence against nematodes by inducing immunoglobulin (Ig) E production and eosinophilia. 
IL-17E is mainly produced by Th2 cells, mast cells and eosinophils, but alveolar 
macrophages, endothelial and epithelial cells can also be the sources of IL-17E
33
. Several 
allergens can induce the expression of IL-17E mRNA in lung epithelial cells suggesting an 
important role of IL-17E in the pathogenesis of allergic lung disease
34
. It seems that the 
regulation of IL-17E is as critical as that of IL-17A in the development of allergic diseases: 
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however, IL-17E induces eosinophilia, while IL-17A recruits neutrophils to the inflammatory 
site. The mechanism, which have role in polarization of the immune response against C. 
pneumoniae towards either type of immunity is unknown.    
 
Cytokine 
Homology 
with 
human (%) 
Source Known function 
IL-17A 63 
Th17 cells; 
CD8
+
 cells; 
γδ T cells; 
NK cells 
induction of pro-inflammatory 
cytokines and chemokines; 
promoting neutrophil recruitment 
IL-17B 88 
chondrocytes; 
neurons 
induction of proliferation of 
chondrocytes; 
promoting neutrophil recruitment 
IL-17C 83 
CD4
+
 cells; DCs; 
macrophages; 
keratinocytes 
promoting neutrophil recruitment 
IL-17D 78 
CD4
+
 cells; B cells; 
skeletal muscle; 
adipose tissue 
stimulating production of IL-6, IL-8 
and GM-CSF by endothelial cells 
IL-17E 
(IL-25) 
81 
CD4
+
 and CD8
+
 cells; 
epithelial and 
endothelial cells; 
eosinophils; mast cells 
promoting Th2 differentiation; 
inducing Th2 cytokines; 
eosinophil recruitment; 
suppression of Th1 and Th17 cell 
responses 
IL-17F 77 
Th17 cells; CD8
+
 cells; 
γδ T cells; epithelial 
cells 
inducing pro-inflammatory cytokines 
and chemokines; 
promoting neutrophil recruitment 
 
Table 1 Members of mouse IL-17 cytokine family
26,33
  
 
 
Chlamydia trachomatis and Chlamydia muridarum 
C. trachomatis is currently divided in 19 serovars, according to the antigenic 
characteristics of the major outer membrane proteins. Different serovariants of C. trachomatis 
cause a wide range of diseases, including blinding trachoma (serovars A-C), urogenital tract 
infections leading to urethritis, cervicitis and proctitis (serovars D-K), and systemic 
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lymphogranuloma venereum disease (serovars L1-L3)
35
. Sexually transmitted C. trachomatis 
infection has an important public-health concern, because in most cases these infections 
produce few or no symptoms and most of them remain undetected and without treatment they 
have adverse effects on reproduction. In women, infection with C. trachomatis causes pelvic 
inflammatory disease, and persistent or repeated infections lead to chronic inflammation 
characterised by scarring of the fallopian tubes and ovaries. Chronic pelvic inflammation has 
long term consequences such as ectopic pregnancy, infertility or chronic pelvic pain
36
. 
Current programmes for the control of C. trachomatis infections are not affordable especially 
in developing countries and might have an inherent weakness; therefore vaccine development 
has been identified as essential measures for the control of infection with C. trachomatis.  
C. muridarum (formerly the C. trachomatis agent of mouse pneumonitis) is a murine 
pathogen that was originally isolated from the lungs of mice. Infection of mice with C. 
muridarum provides a useful model of C. trachomatis infection in humans
37
. The genomes of 
C. muridarum and C. trachomatis serovar D display notable similarity in the content and 
order of genes, with the exception of a region of 50 kb from the origin of termination, deemed 
the plasticity zone
38
. Studies of infection with C. muridarum have revealed that the murine 
innate and adaptive immune responses to infection are closely similar to the immune 
responses in women infected with C. trachomatis
39
. Elucidation of the immunobiology of C. 
muridarum infection of mice helps to guide the interpretation of immunological findings in 
studies of human C. trachomatis infection. Identification of the antigens, which elicit immune 
responses and protection against the pathogen, is an important priority in C. trachomatis 
research.  
Animal models have clearly disclosed that T cells, especially the IFN-γ-producing CD4+ 
cells have a crucial role in the resolution of C. trachomatis infection. By contrast, B cells and 
antibodies are probably important for resistance to secondary infection
40
. Host genetic factors 
appear to be important in determining the outcome of C. trachomatis infections. It has been 
reported that the increased incidence of chlamydia-induced chronic diseases, such as scarring 
trachoma and tubal infertility, correlates with the carriage of certain human leukocyte antigen 
haplotypes and the polymorphism of genes encoding tumour necrosis factor-α (TNF-α), IL-10 
and CD14
41–44
. Similarly to humans, inbred mouse strains with different haplotypes, such as 
C3H/HeN, C57BL/6N, BALB/c and DBA/2 mice, respond differently to respiratory 
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chlamydial infections
45–47
. C3H/HeN mice are more susceptible to C. muridarum lung 
infection, with more severe morbidity and higher mortality compared to C57BL/6N mice, 
even though both strains display similar Th1-like response
45
.  
 
The chlamydial cryptic plasmid 
Bacterial plasmids bear genes considered to be non-essential for host cell survival, but 
confer selective advantages for survival in specific environments
48
. Several Chlamydia 
species harbour a highly conserved plasmid with an approximate size of 7.5 kb
49
. The plasmid 
of C. trachomatis encodes both noncoding RNAs and eight open reading frames (ORFs), 
while the plasmid of C. muridarum (pMoPn) possesses seven ORFs, designated TCA01-07 
(Fig. 2). All plasmid-borne genes are transcribed and translated. TCA04 and TCA05 encode 
the proteins pGP3 and pGP4, respectively
50
. Naturally occurring plasmid-deficient clinical 
isolates are extremely rare
51
. Studies with plasmid-deficient C. trachomatis and C. muridarum 
have implicated the chlamydial plasmid as a key virulence factor in vivo, because infection 
with plasmid-deficient organisms are either asymptomatic or exhibits significantly reduced 
pathology
52,53
.   
Putative functions for several ORFs have been assigned on the basis of homology to 
known proteins in the public databases: pGP1 a DnaB like helicase; pGP7 and -8 
integrase/recombinase homologues; pGP5 homologue to partitioning protein ParA
54
. The 
usage of deletion mutagenesis and chlamydial transformation was recently described as a new 
possibility for the genetic characterisation of the function of plasmid ORFs
55
. According to 
this, the ORFs can be grouped into two sets: essential ORFs (pGP1, -2, -6 and -8) and non-
essential ORFs (pGP3, -5 and -7) for stable plasmid maintenance in tissue culture. In addition, 
the plasmid functions as a transcriptional regulator of various chromosomal genes, which may 
play important roles in chlamydial pathogenicity, and pGP4 has been demonstrated to be the 
protein that positively regulates the transcription of plasmid-encoded pGP3 and multiple 
chromosomal genes during C. trachomatis infection and pGP5 is the negative regulator of the 
same set of chromosomal genes
56–58
.  
The roles of the plasmid-encoded or regulated proteins in either chlamydial pathogenesis 
or protective immunity remain largely unknown, but the plasmid-mediated virulence is linked 
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to enhanced pro-inflammatory cytokine stimulation by the activation of TLRs in a murine 
model
59
. pGP3, the most intensively studied plasmid protein, has been found to be secreted 
into the host cell cytosol during chlamydial infections; it has been implicated as a potential 
TLR agonist, because purified pGP3 induced both TNF-α and IL-8 production in 
macrophages in vitro
60
. pGP3 is an immunodominant antigen in women infected with C. 
trachomatis in the urogenital tract; it is recognized by human antibodies in enzyme-linked 
immunosorbent assay (ELISA)
61
. Although, the human antibody recognition of pGP3 is 
dependent on the native conformation of the protein: pGP3 trimerisation is required for the 
recognition of pGP3 by human antibodies
62
. DNA immunisation with the plasmid expressing 
pGP3 of C. trachomatis was demonstrated to inhibit the spread of C. trachomatis infection 
from the lower to the upper genital tract in C3H/HeN mice
63
.  
Increased knowledge of the role of the cryptic plasmid in biology and pathogenesis will 
enhance our understanding of chlamydial growth and development, and will be important for 
guiding the design of a vaccine for the prevention of chlamydial disease.  
 
Fig. 2 Graphics of C. muridarum Nigg and C. trachomatis D plasmid created with CLC Sequence Viewer 6.4 
software
64
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Aims 
The present study was designed to address the following aims:  
 
Aim 1. To determine the roles of IL-17 cytokines in pathological immune response to C. 
pneumoniae and C. muridarum infection and re-infection in BALB/c mice 
 
Aim 2. To describe the transcriptional pattern of pMoPn genes in C. muridarum-infected 
BALB/c and C57BL/6N mice 
 
Aim 3. To compare the host immune response against pGP3 and pGP4 after C. muridarum 
infection and re-infection in BALB/c and C57BL/6N mice 
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Materials and methods 
 
Propagation of chlamydial strains and culturing of chlamydiae from the lungs of mice 
C. pneumoniae CWL029 (purchased from the American Type Culture Collection) and C. 
muridarum strain Nigg (a kind gift from H.D. Caldwell, Hamilton, MT, USA) were 
propagated on HEp-2 and McCoy cells, respectively, and purified, as described earlier
65
. The 
purified and concentrated EBs were aliquoted and stored at -80 °C until use. The titre of the 
infectious EBs was determined by indirect immunofluorescence assay. Serial dilutions of the 
EB preparation were inoculated onto cell monolayers and, after 24 or 48 h culture, cells were 
fixed with acetone and stained with monoclonal anti-Chlamydia LPS antibody (AbD Serotec, 
Oxford, UK) and fluorescein isothiocyanate (FITC)-labelled anti-mouse IgG (Sigma, Saint 
Louis, MO, USA). The number of chlamydial inclusions was counted under a UV 
microscope, and the titre was expressed in inclusion forming unit (IFU)/ml. A mock 
preparation was prepared from uninfected cells processed in the same way as the infected 
cells. Lung homogenates from each mouse were centrifuged (10 min, 400g), serial dilutions 
of the supernatants were inoculated onto cell monolayers, and the titre of C. pneumoniae or C. 
muridarum was determined. 
 
Experimental animals 
Specific pathogen-free 6-8-week-old female BALB/c and C57BL/6N mice were obtained 
from INNOVO Kft. (Budapest, Hungary). The mice were maintained under standard 
husbandry conditions at the animal facility of the Department of Medical Microbiology and 
Immunobiology, University of Szeged, and were provided with food and water ad libitum. All 
experiments fully complied with the University of Szeged Guidelines for the Use of 
Laboratory Animals. 
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Model of infection and re-infection with C. pneumoniae 
Before infection, BALB/c mice were mildly sedated with an intraperitoneal (i.p.) 
injection of 200 l of sodium pentobarbital (7.5 mg/ml); they were then infected intranasally 
with 5×105 IFU of C. pneumoniae in 25 l of sucrose-phosphate-glutamic acid (SPG) buffer. 
Control mice were also mildly sedated but left uninfected. After inoculation, mice were 
anaesthetized and sacrificed on days 1, 2, 4, 7, 14 or 28, 7 animals at each time point. Sera 
were taken by cardiac puncture. The lungs were removed and homogenized mechanically. 
Half of the homogenized lungs was processed for quantitative reverse transcription 
polymerase chain reaction (RT qPCR), while the other half was suspended in 1 ml of SPG 
buffer for the detection of viable C. pneumoniae, and for cytokine and chemokine 
measurements. Spleens were destroyed with a cell strainer, and the spleen cells were kept in 
foetal bovine serum medium containing dimethyl sulfoxide at -80 °C until use.  
In a separate experiment, BALB/c mice were infected intranasally 3 times with viable C. 
pneumoniae (5×105 IFU) or with heat-inactivated C. pneumoniae (concentrated EBs were 
kept at 90 °C for 30 min) at 4-week intervals. Another group of mice were initially infected 
with viable C. pneumoniae and then infected twice with heat-inactivated C. pneumoniae at 4-
week intervals. Groups of 7 mice were sacrificed at 2 or 4 weeks after each infection and the 
lungs were processed as mentioned above. 
 
Model of infection and re-infection with C. muridarum 
Before infection, BALB/c mice were mildly sedated with an i.p. injection of 200 μl of 
sodium pentobarbital (7.5 mg/ml); they were then infected intranasally with 1×103 IFU of C. 
muridarum in SPG buffer; half of the mice were re-infected 28 days after the first infection. 
Seven mice at each time point were anaesthetized and sacrificed on each of days 1, 7, 14, 28, 
29, 35, 42 and 56 after the first infection. Sera were taken by cardiac puncture. The lungs 
were removed and homogenized. One half of the homogenized lungs was processed for RT 
qPCR, while the other half was suspended in 1 ml of SPG for the detection of viable C. 
muridarum. Lungs of three mice from each group were removed, frozen and kept at -80 °C 
for immunofluorescent staining.  
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In a separate experiment BALB/c and C57BL/6N mice were infected intranasally with C. 
muridarum 3 times at 4-week intervals. Groups of 7 mice were sacrificed at 2 weeks after 
each infection. Sera were taken by cardiac puncture. Spleens were dissected and homogenized 
by pressing through a nylon mesh into complete growth medium for testing of cell-mediated 
immunity. 
 
mRNA extraction from the lungs of mice and RT qPCR 
Total RNA was extracted from the lung suspensions by using the TRI Reagent (Sigma). 
During purification, all samples were treated with DNase 1, Amplification Grade (Sigma) to 
remove genomic DNA contamination. The RNA was quantified by spectrophotometric 
analysis and the RNA integrity was confirmed by agarose gel electrophoresis. First-strand 
cDNA was synthesized by using 2 g of total RNA with Superscript III (Invitrogen Carlsbad, 
CA, USA) and 20 pmol of random hexamer primers in 20 l of reaction buffer. The cDNA 
product was diluted 1/30, and the qPCR was conducted with the diluted cDNA, primers (10 
pmol/μl) and SYBR® Green JumpStartTM Taq ReadyMixTM (Sigma) in a total volume of 20 
l, with a CFX96 Touch real-time PCR detection system (Bio-Rad, Hercules, CA, USA). 
Primer sequences used for qPCR are given in Table 2, all primers were synthesized by 
Integrated DNA Technologies Inc. (Montreal, Quebec, Canada). Thermal cycling was 
initiated with a denaturation step of 10 min at 95 °C, followed by 40 cycles each of 5 sec at 95 
°C, 20 sec at 60 °C and 25 sec at 72 °C. Dissociation curves were recorded after each run to 
ensure primer specificity. Cycle threshold (Ct) values were determined by automated 
threshold with Bio-Rad CFX Manager Software version 1.6. The lowest cycle number at 
which the various transcripts were detectable, referred to as Ct, was compared with that of -
actin in the case of different IL-17 transcripts, the difference being referred to as ΔCt. The 
lowest cycle number at which the transcripts of pMoPn were detectable was compared with 
that of 16s rRNA of C. muridarum, as this gene was previously shown to be an accurate 
normalizing gene for gene expression analysis in C. trachomatis
66
. The relative expression 
level was given as 2
-(ΔΔCt), where ΔΔCt = ΔCt for the experimental sample minus ΔCt for the 
control sample. Mice sacrificed 4 h after infection with C. pneumoniae or C. muridarum 
served as controls. We defined a threshold value, i.e. increases greater than 2-fold in the 
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amount of transcripts relative to control samples were considered significant. Each sample 
was assayed in triplicate, and each experiment was performed at least twice. 
 
Target gene 
(Gene ID) 
Forward primer (5’-3’) Reverse primer (5’-3’) 
IL-17A 
mRNA 
(16171) 
AAGGCAGCAGCGATCATCC 
GGAACGGTTGAGGTAGTCTGA
G 
IL-17C 
mRNA 
(234836) 
TGCTGAGGAATTATCTCAC
GGCCA 
ACTGTGTTCCAGCTAGAGGTCC
TT 
IL-17D 
mRNA 
(239114) 
CAAGCACATCACACACATC
CCGTT 
TTAGTAAGCTTGGGCCACAGG
AGA 
IL-17E 
mRNA  
(140806) 
CAGGTGTACCATCACCTTG
CCAAT 
ACAACAGCATCCTCTAGCAGC
ACA 
IL-17F 
mRNA 
(257630) 
AGCAAGAAATCCTGGTCCT
TCGGA 
CTTGACACAGGTGCAGCCAAC
TTT 
IL-23 p19 
mRNA 
(83430) 
CCTGCTTGACTCTGACATC
TTC 
TGGGCATCTGTTGGGTCTC 
-actin 
mRNA 
(11461) 
TGGAATCCTGTGGCATCCA
TGAAA 
TAAAACGCAGCTCAGTAACAG
TCCG 
TCA01 
(1245522) 
GCTTCGGAGCGCAATGACA
ACTAA 
ACAGAAGAGTTCCCGCCAGAA
CAA 
TCA02 
(1245521) 
AGAGCGTGCATGAACTTCT
GAGGA 
ACTATGCTGCAAGGAGGTAAG
CGT 
TCA03 
(1245519) 
TGGGAAGAGCTGTTAAGAA
GGCGT 
CGTATGCGAAATAGGCCTGAG
CTT 
TCA04 
(1245520) 
ACTTGGGACATCGACAACT
CCTGT 
CCATCAAAGATTTGGTCGCCAA
GC 
TCA05 
(1245517) 
CACCCTTAGAACTCTACCA
CAAGAG 
TCTAGACAGAATAAGCATAAT
CAACGCT 
TCA06 
(1245518) 
AGCATCGAAGGCAACCATA
AAGGC 
AACAGCCGTAAATTGCTGCTTG
GG 
TCA07 
(1245523) 
ACAACACGTGCTCCTTCTT
GGAGA 
AGCCAACGCATTATAGGCGGA
TGA 
16s rRNA 
(444439667) 
CATGCATATGACCGCGGCA
GAAAT 
ACCCTAAGTGCTGGCAACTAA
CGA 
 
Table 2 Primer sequences used for qPCR 
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Cytokine and chemokine measurements  
The supernatants of the lung homogenates were centrifuged (5 min, 12 000g) and assayed 
for the concentrations of IL-17A, KC, LIX and MIP-2 with different Quantikine® mouse 
chemokine/cytokine kits (R&D Systems, Minneapolis, MN, USA), while the quantity of IL-
17E was determined with Ready-SET-Go! kit (eBioscience Inc., San Diego, CA, USA). The 
sensitivities of the IL-17A, KC, LIX, MIP-2 and IL-17E measurements were in the ranges 
10.9-700 pg/ml, 15.6-1000 pg/ml, 15.6-1000 pg/ml, 7.8-500 pg/ml and 31.2-2000 pg/ml, 
respectively. The clarified supernatants were tested in duplicate in accordance with the 
manufacturer’s instructions. 
 
ELISPOT assay 
ELISPOT assays were performed to determine the number and phenotype of the IL-17A-
producing spleen cells isolated from BALB/c mice 2 weeks after C. pneumoniae infection, 
uninfected mice served as controls. To determine the phenotype of the IL-17A-producing 
cells, the spleen cell suspensions were depleted of CD4
+
 and CD8
+
 cells, respectively, by 
using micro-beads coated with the respective antibody [α-CD4 (L3T4) or α-CD8a (Ly-2), 
Miltenyi Biotec, Bergisch Gladbach, Germany] and applying the magnetic cell sorting system 
of Miltenyi Biotec. The outcome of the procedure was controlled by flow cytometry after 
direct staining of the depleted cells with α-CD4-TC and α-CD8-rPE antibodies (Caltag 
Laboratories, Burlingame, CA, USA). The numbers of left-over CD4
+
 and CD8
+
 cells after 
the depletion process were <1%. Spleen cells were re-stimulated in vitro with heat-inactivated 
C. pneumoniae EBs at a multiplicity of infection of 0.2, or with an equivalent amount of 
mock preparation. To determine the number of IL-17A-producing cells, IL-17A ELISpot kit 
(R&D Systems) was used. Stimulated spleen cells (5×105) were distributed into each well in 
triplicate in accordance with the manufacturer’s instructions. The mean number of spots 
counted in triplicate wells under a dissecting microscope was used to calculate the number of 
spot-forming cells (SFCs) per 1 million spleen cells. 
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In vivo neutralization of IL-17A in mice and bronchoalveolar lavage fluid collection 
Groups of 14 female BALB/c mice were treated i.p. with 100 g/mouse of either anti-IL-
17A (MAB421, R&D Systems) or an isotype control antibody (R&D Systems) 24 h before 
and 1 and 2 days after C. pneumoniae infection. The mice were sacrificed on day 1 or day 4 
after infection and the lungs of 7 mice from each group were lavaged with 1 ml of phosphate-
buffered saline (PBS). 50 l of a 5×105 cells/ml cell suspension was placed into a chamber 
which was attached to cytospin slides, and then centrifuged at 800 rpm for 3 min. The cells 
were examined morphologically and counted after staining with May-Grünwald-Giemsa 
solution. The lungs of 7 mice from each group were removed and chlamydial burden was 
determined as mentioned above. 
 
Lung histopathology 
Four weeks after C. muridarum infection and re-infection BALB/c mice were 
anaesthetized and then sacrificed by exsanguination through cardiac puncture. Uninfected 
mice were used as controls. The lungs were removed in toto and immersed in frozen tissue 
matrix, OCT (Sakura Finetek Europe, Alphen aan den Rijn, the Netherlands). For the 
detection of IL-17E antigen by immunofluorescence test, lungs were cut into 5-m sections. 
The sections were stained with IL-17E antibody (Acris Antibodies GmbH, Herford, Germany) 
as primary antibody for 45 min at room temperature, followed by staining for 30 min with 
FITC-labelled anti-mouse IgG antibody (Sigma).  
 
Cloning and over-expression of plasmid genes 
723 and 309 bp DNA fragments containing TCA04 and TCA05 (GenBank ID 
10957566:4703-5425, Locus tag TCA04 and GenBank ID 10957566:5494-5802, Locus tag 
TCA05) were amplified by PCR, C. muridarum Nigg strain DNA being used as template. The 
PCR was performed in a GeneAmp II (Applied Biosystems, Foster City, CA, USA) 
thermocycler with Advantage GC cDNA polymerase (Clontech, Mountain View, CA, USA), 
under the amplification conditions recommended by the manufacturer. The amplicon was 
digested with NdeI and EcoRI and inserted into the p6HisF-11d (icl) pET vector
67
 by 
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digesting it with the same enzymes and replacing the icl gene. For overexpression, 
Escherichia coli HB101 (Invitrogen) cells carrying this plasmid were grown and treated 
according to the method of Tabor and Richardson
68
. Briefly, cells containing the plasmids 
were grown at 32 °C on Luria-Bertani agar plates in the presence of the required antibiotics. 
Over-expression of these proteins was induced by shifting the temperature to 42 °C for 20 
min. After induction, the temperature was shifted down to 37 °C for an additional 90 min, 
cells were harvested by centrifugation, and the pellet was kept at -20 °C until use. 
 
Purification of plasmid proteins 
Cell lysates from E. coli were prepared by suspending the frozen cells in CelLytic B-II 
(Sigma) with protease inhibitors. Recombinant protein was purified by using TALON 
CellThru Resin (Clontech) according to the manufacturer's instructions. 
 
Western blot 
Purified pGP3, pGP4 and C. muridarum EBs were boiled for 5 min in 4x Dual Color 
Protein Loading Buffer (Fermentas GmbH, St. Leon-Rot, Germany), and 2 µg of proteins 
were separated by sodium dodecyl sulfate-10% polyacrylamide gel electrophoresis. The 
separated proteins were blotted onto a polyvinylidene difluoride membrane (SERVA, 
Heidelberg, Germany). The membranes were blocked overnight at 4 °C with 5% skim milk 
and 0.05% Tween 20 (Sigma) containing PBS. Membranes were probed with a pool of 
uninfected mice sera or sera obtained from C. muridarum-infected BALB/c or C57BL/6N 
mice (1:50 dilution in 5% skim milk and 0.05% Tween 20 containing PBS). After washings, 
the filter was incubated with HRP-conjugated anti-mouse IgG (Sigma), and the colour was 
developed with diaminobenzidine tetrahydrochloride (Sigma–Aldrich Chemie GmbH, 
Steinheim, Germany) with hydrogen peroxide in 10 mM Tris, pH 7.5. 
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Identification of proteins by mass spectrometry 
The gel slices containing the polypeptides of corresponding proteins which were 
recognized by the sera of C. muridarum-infected BALB/c mice in the blot assay were cut out 
from the gel and analysed by mass spectrometry. Briefly, protein bands were diced and 
washed with 25 mM NH4HCO3 in 50% (v/v) acetonitrile/water. Disulphide bridges were 
reduced with dithiothreitol, and free sulfhydryl groups were alkylated with iodoacetamide. 
Proteins were digested with modified porcine trypsin (Promega, Madison, WI, USA) for 4 h 
at 37 °C. Samples were analysed by liquid chromatography-tandem mass spectrometry (LC-
MS/MS). The raw LC-MS/MS data were converted into a Mascot generic file with Mascot 
Distiller software (v2.1.1.0). The resulting peak lists were searched by using the Mascot 
Daemon software (v2.2.2) against the NCBI non-redundant database without species 
restriction (NCBInr 20080718, 6833826 sequences). Monoisotopic masses with a peptide 
mass tolerance of ±0.6 Da and a fragment mass tolerance of 1 Da were submitted. 
Carbamidomethylation of Cys was set as a fixed modification, and acetylation of protein N-
termini, Met oxidation, and pyroglutamic acid formation from peptide N-terminal Gln 
residues were permitted as variable modifications. Acceptance criteria were at least 2 
individual peptides with a minimum peptide score of 55 per protein. 
 
Lymphocyte proliferation assay 
Single-cell suspensions from 2 spleens of triple C. muridarum-infected or uninfected 
BALB/c and C57BL/6N mice were pooled and re-suspended in the complete growth medium. 
The proliferative responses of 5×105 spleen cells in 3 parallel wells to 2 μg/ml of pGP3 or 
pGP4 recombinant protein, purified heat-inactivated C. muridarum EBs (1 μg/ml), or the 
similarly treated mock preparation were detected after incubation for 3 days. The proliferation 
was determined by MTT assay (Boehringer Mannheim Biochemica, Mannheim, Germany) 
according to the manufacturer's instructions. Stimulation indices (SIs) were calculated by 
dividing the optical density measured for protein-, mock- or EB-stimulated spleen cells by the 
optical density measured for non-stimulated spleen cells.  
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Statistical analysis 
Statistical analysis of the data was carried out with SigmaPlot for Windows Version 11.0 
software, using the Wilcoxon–Mann–Whitney two-sample test. Differences were considered 
statistically significant at p<0.05.  
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Results 
 
Aim 1. To determine the roles of IL-17 cytokines in pathological immune response to C. 
pneumoniae and C. muridarum infection and re-infection in BALB/c mice 
 
C. pneumoniae infection induces the expression of IL-17A and IL-17F mRNA in the lungs 
of BALB/c mice 
In order to investigate the production of different IL-17 cytokines during C. pneumoniae 
infection, BALB/c mice were infected intranasally with C. pneumoniae. On days 1, 2, 4, 7, 14 
or 28 after infection, mice were sacrificed and their lungs were removed for the determination 
of C. pneumoniae titres, the expression of the different IL-17 (IL-17A, C, D, E, F) and IL-23 
mRNA, and the IL-17A protein content in the individual lungs. 
The infectious bacterial titre was below the level of detectability at 24 h after infection, 
but it had increased by day 2. The peak titre of C. pneumoniae was observed on day 7, while 
on day 14 after infection the titre had decreased and no viable C. pneumoniae was detected on 
day 28 (App. I. Fig. 1a). The expression of IL-17A mRNA was increased as early as on day 
2, but the highest level of expression (26.1-fold) was detected on day 7 after infection. It then 
decreased continuously, but the expression level was still rather high relative to the control on 
day 28 (Fig. 3A). The expression of IL-17F mRNA was highest on day 4 (16.25-fold) and 
then decreased during the observation period. The expression of IL-17C, IL-17D and IL-17E 
mRNA did not change during the course of C. pneumoniae infection. The mRNA expression 
of IL-23, the main inducer of IL-17A production, was observed on the first day, and peaked 
on day 2 at 62-fold (Fig. 3B). The kinetics of IL-17A protein production correlated with the 
mRNA expression: it increased from day 2, with the highest concentration on day 7 (App. I. 
Fig. 1d). 
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Fig. 3 Expression of different IL-17 mRNA (A) and IL-23 mRNA (B) in lung suspensions from C. pneumoniae-
infected BALB/c mice. The line denotes a threshold value, which was set at a 2-fold increase in transcripts. Data 
are normalized for -actin RNA content and plotted as fold change over the results for the control mice. Bars 
denote mean ± SD of the results on 7 mouse lungs. 
 
 
CD4
+
 cells are the main source of IL-17A in C. pneumoniae-infected BALB/c mice 
To define the phenotype and the number of peripheral cells which release IL-17A, 
ELISPOT assay was carried out with the spleen cells of C. pneumoniae-infected mice after 
the depletion of CD4
+
 or CD8
+
 cells and in vitro re-stimulation with heat-inactivated C. 
pneumoniae or mock preparation. Spleen cells of uninfected mice served as controls.  
C. pneumoniae infection caused a significant increase in the number of IL-17A-
producing cells after in vitro re-stimulation of the spleen cells with heat-inactivated C. 
pneumoniae, as compared with the spleen cells of uninfected mice (data not shown). In vitro 
re-stimulation of spleen cells isolated from C. pneumoniae-infected mice with heat-
inactivated C. pneumoniae significantly enhanced the number of IL-17A-producing cells as 
compared with spleen cells re-stimulated with mock preparation (Fig. 4). The depletion of 
CD8
+
 cells did not result in a reduction in the number of IL-17A-producing cells, whereas the 
depletion of CD4
+
 cells resulted in a significant reduction in the number of SFCs in in vitro 
re-stimulated spleen cells isolated from C. pneumoniae-infected mice. These results indicate 
that the CD4
+
 cells are the main source of IL-17A during C. pneumoniae infection in BALB/c 
mice. 
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Fig. 4 The number of IL-17A-producing cells isolated from C. pneumoniae-infected mice and tested after 
depletion of CD4
+
 and/or CD8
+
 cells and in vitro re-stimulation with heat-inactivated C. pneumoniae or mock in 
ELISPOT assay. Bars indicate mean ± SD of SFCs per million spleen cells, counted in triplicate wells 
(*p<0.001). 
 
 
In vivo neutralization of IL-17A resulted in higher bacterial burden in the lungs of C. 
pneumoniae-infected BALB/c mice  
To investigate the role of IL-17A in acute C. pneumoniae infection, mice were treated 24 
h before, and 24 and 48 h after the infection with anti-IL-17A monoclonal antibodies or with 
isotype control antibodies. Mice were sacrificed on day 1 or 4 after infection. The numbers of 
lymphocytes, macrophages and neutrophil granulocytes in the BAL fluid of the mice were 
determined. From the homogenized lungs, C. pneumoniae was cultured and the levels of 
different cytokines were determined by ELISA. 
The in vivo anti-IL-17A treatment led to a significantly reduced IL-17A content in the 
BAL fluid on day 4 as compared to that in the control mice. The numbers of neutrophil cells 
in the anti-IL-17A-treated group on days 1 and 4 were significantly lower than those for the 
control. Neutralization of IL-17A did not influence the numbers of macrophages and 
lymphocytes in the BAL fluid (App. I. Table 1). The number of viable chlamydiae in the 
lung suspension of the anti-IL-17A-treated group on day 4 was significantly higher than the 
C. pneumoniae content of the lungs of control mice (Fig. 5A). The levels of KC and MIP-2 on 
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day 4 were significantly lower than the chemokine levels in the lungs of the control mice (Fig. 
5B). 
 
Fig. 5 The number of viable C. pneumoniae (A) and the levels of KC, MIP-2 and LIX (B) in the lungs of anti-IL-
17A-treated and control mice on day 4 after infection. Bars denote mean ± SD of the results on 7 mouse lungs 
(*p<0.05). 
 
 
C. pneumoniae re-infection triggers the production of IL-17A and IL-17E in BALB/c mice 
In order to study the role of IL-17A and IL-17E in chronic chlamydial infection, BALB/c 
mice were infected intranasally with C. pneumoniae 3 times at 4-week intervals, and were 
sacrificed at 14 or 28 days after each infection, their lungs were collected for the 
determination of C. pneumoniae titres, the expression of IL-17A and IL-17E mRNA, and the 
IL-17A/E protein content in the individual lungs. 
After the first infection, the quantity of recoverable C. pneumoniae was similar to that in 
the previous experiment. After the second and third infections, C. pneumoniae was not 
detected in the lungs of the mice at the examined time points (data not shown). The re-
infection of the mice with C. pneumoniae induced the production of IL-17A and the 
expression pattern was similar to that measured after the first infection, but the expression 
levels were higher, in spite of the absence of viable chlamydiae in the lungs of mice. The 
expression of IL-17E mRNA was not increased after a single infection, but after the second 
and third infections its expression increased dramatically. The expression level of IL-17E 
mRNA 4 weeks after the third C. pneumoniae infection was still 400 times higher than that in 
the control lungs (Fig. 6A).  
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To clarify whether viable C. pneumoniae is needed to induce IL-17A/E mediated 
pathological immune response or only the chlamydial antigens are sufficient, mice were first 
infected intranasally with viable or heat-inactivated C. pneumoniae then infected twice with 
heat-inactivated C. pneumoniae at 4-week intervals. The mice were sacrificed at 2 or 4 weeks 
after infection and the expression of IL-17A and IL-17E mRNA was determined.  
We observed a significant increase in the expression of IL-17A mRNA in the lungs of 
mice infected first with viable C. pneumoniae and then with heat-treated C. pneumoniae on 
the second and third occasions (App. I. Fig. 4b). However, the expression of IL-17E mRNA 
was not detectable in the lungs of these mice. We found that the infection and re-infection of 
mice with heat-inactivated C. pneumoniae did not influence the expression of IL-17A and IL-
17E mRNA in the lungs of the mice (data not shown). 
Fig. 6 The expression of IL-17A and IL-17E mRNA in the lungs of BALB/c mice infected and re-infected with 
C. pneumoniae (A) or C. muridarum (B). ↓ denotes the time of re-infection. The line denotes a threshold value, 
which was set at a 2-fold increase in transcripts. 
 
 
C. muridarum infection and re-infection induce the expression of IL-17A and IL-17E 
mRNA in the lungs of BALB/c mice 
In order to investigate the production of IL-17A and IL-17E during C. muridarum 
infection, BALB/c mice were infected intranasally with C. muridarum, and re-infected on day 
28 after the first infection. On days 1, 7, 14, 28, 29, 35, 42 and 56 after the first infection, 
mice were sacrificed and their lungs were removed for the determination of bacterial burden, 
mRNA levels and protein contents of the IL-17A and IL-17E cytokines in individual lungs. 
Days post-infection
1 14 28 42 70 84
F
o
ld
 i
n
c
re
a
s
e
 i
n
 t
ra
n
s
c
ri
p
ts
0
20
40
60
80
100
200
300
400
500
IL-17A
IL-17E
Days post-infection
1 7 14 28 29 35 42 56
F
o
ld
 i
n
c
re
a
s
e
 i
n
 t
ra
n
s
c
ri
p
ts
0
50
100
150
200
250
300
800
1000
1200
1400
1600 IL-17A
IL-17E
A B 
 31 
The course of chlamydial burden in the lungs of mice was similar to that detected during 
C. pneumoniae infection: the number of C. muridarum increased by day 1, peaked on day 7, 
and then decreased by day 28 after infection. On day 29, one day after the re-infection the 
bacterial titre was increased but at later time points, viable C. muridarum was not detected in 
the lungs of the re-infected mice (App. II. Fig. 1).   
The expression of IL-17A mRNA displayed similar kinetics as after infection and re-
infection with C. pneumoniae, it was highest on day 7, then decreased continuously. The fold 
increase in IL-17A transcripts was higher after re-infection than it was after the primary 
infection. Unlike that of IL-17A mRNA, the expression of IL-17E mRNA did not 
demonstrate a parallel change with the level of bacterial burden in the lungs of the mice. The 
expression started to increase on day 7, and the highest level was detected on day 28 after the 
first infection. On day 29 (one day after re-infection), the expression of IL-17E mRNA 
decreased dramatically, but after that it increased again and was highest 28 days after re-
infection, when the experiment was terminated (Fig 6B). In the lungs of the infected and the 
re-infected mice the kinetics of IL-17A and IL-17E protein production was similar to that of 
the expression of IL-17A and IL-17E mRNA, respectively (App. II. Fig. 2b). 
 
 
The epithelial cells of the lung are responsible for the production of IL-17E after C. 
muridarum infection and re-infection  
To reveal which cells are responsible for the production of IL-17E in the later stage of C. 
muridarum infection and re-infection, the lungs of infected, re-infected and uninfected mice 
were sectioned and stained with monoclonal antibody to IL-17E as primary, and FITC-
labelled anti-mouse IgG as a secondary antibody.  
No fluorescence was seen in the lung sections of the uninfected mice (Fig. 7A). 
Production of IL-17E was observed in the lungs of the infected and re-infected mice four 
weeks after infection. The IL-17E-positive cells were situated especially among the epithelial 
cells of the bronchi, and only a few positive cells were found in the interstitium of the lungs 
(Fig. 7B and C). 
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Fig. 7 The production of IL-17E in the lungs of uninfected (A), C. muridarum-infected (B) and re-infected mice 
(C). The lung sections were stained with IL-17E-specific monoclonal antibody and with FITC-labelled anti-
mouse IgG. 
 
 
 
Aim 2. To describe the transcriptional pattern of pMoPn genes in C. muridarum-infected 
BALB/c and C57BL/6N mice 
 
The pMoPn genes displayed divergent transcriptional pattern in BALB/c mice and in 
C57BL/6N mice  
In order to compare the susceptibility of BALB/c mice and C57BL/6N mice to C. 
muridarum infection, mice were infected intranasally with 1×103 IFU of C. muridarum and 
sacrificed 1, 7, 14, 28 or 56 days after infection, and the chlamydial burden was determined in 
the lungs of mice.  
From the first day after the infection, the BALB/c mice displayed more clinical 
symptoms than did the C57BL/6N mice, as indicated by ruffled fur, passivity, a lack of 
appetite and weight loss. In BALB/c mice, the infectious C. muridarum titre was increased on 
day 1, peaked on day 7, and then decreased continuously. On day 28 after infection, the viable 
C. muridarum titre was 3×101 IFU/lung, but there was no detectable C. muridarum on day 56 
after infection. In C57BL/6N mice, the peak titre of C. muridarum was also detected on day 7. 
However, by day 28 post-infection, all of the C57BL/6N mice were culture-negative, whereas 
all of the BALB/c mice remained culture-positive (App. III. Fig. 1).  
A B C 
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To compare the transcriptional pattern of pMoPn genes in BALB/c and C57BL/6N mice 
during C. muridarum infection, RT qPCR was carried out with total RNA isolated from the 
lungs of infected mice.  
Increased levels of expression of different plasmid genes were observed in the BALB/c 
mouse lungs on day 7 after infection. The expression of TCA01, TCA02, TCA03, TCA06 and 
TCA07 was 3-5-fold higher on day 7 relative to that in the control sample, and increased 
further to 5-7-fold on day 14. Interestingly, the increases in the expression of TCA04 and 
TCA05 in the BALB/c mice were each 3-fold on both day 7 and day 14 (Fig. 8A). In 
C57BL/6N mice, the expression of pMoPn genes was delayed. However, on day 14 the 
expression levels of the plasmid genes in C57BL/6N mice were higher (7-47-fold) than those 
in BALB/c mice (Fig. 8B). There was no plasmid-encoded gene expression on day 28 after C. 
muridarum infection in either mouse strain. 
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Fig. 8 Expression levels of pMoPn genes in the lungs of BALB/c mice (A) and C57BL/6N mice (B). The line 
denotes a threshold value, which was set at a 2-fold increase in transcripts.  
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Aim 3. To compare the host immune response against pGP3 and pGP4 after C. 
muridarum infection and re-infection in BALB/c and C57BL/6N mice 
 
Infection and re-infection with C. muridarum induced the production of pGP3- or pGP4-
specific antibodies in C57BL/6N mice but not in BALB/c mice 
To clarify whether pGP3 and pGP4 are able to induce the production of specific 
antibodies or not in C. muridarum-infected mice, BALB/c and C57BL/6N mice were infected 
with C. muridarum 3 times at 4-week intervals. Mice were sacrificed 14 days after infection, 
sera were taken, and Western blot analysis was performed. Recombinant, purified pGP3 or 
pGP4 protein or C. muridarum EBs served as antigens, and sera collected from uninfected 
mice were used as controls. 
In C57BL/6N mice, a single infection with C. muridarum was sufficient to induce the 
production of pGP3-specific antibodies (Fig. 9A panel b-d). No pGP4-specific antibody 
production was detected in mice infected once or twice, but this antibody appeared after the 
3rd infection (Fig. 9A panel d). Contrarily, the sera of C. muridarum-infected and re-infected 
BALB/c mice did not react with the pGP3 and the pGP4 (Fig. 9B panel b-d). The sera of 
uninfected mice did not contain pGP3-, pGP4- or C. muridarum-specific antibodies (Fig. 
9A,B panel a). Sera of C. muridarum-infected mice reacted with the lysate of concentrated C. 
muridarum EBs.  
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Fig. 9 Production of pGP3- and pGP4-specific antibodies in C57BL/6N mice (A) and in BALB/c mice (B) 
infected 1-3 times with C. muridarum as tested in Western blot assay. Purified C. muridarum EBs or pGP3 or 
pGP4 were loaded onto a denaturing polyacrylamide gel. After electrophoresis, the gel was blotted onto a PVDF 
membrane for Western blot detection with pooled sera of mice infected 1 (panel b), 2 (panel c) or 3 times 
(panel d) with C. muridarum. A serum sample pooled from uninfected mice was used as a negative control 
(panel a).  
 
 
Sera of C. muridarum-infected BALB/c mice recognized only the trimeric form of pGP3  
 Although the sera of C. muridarum-infected and re-infected BALB/c mice did not react 
with the 28 kDa pGP3, but they reacted with an additional protein with 80-85 kDa (Fig. 9B 
panel b-d). As it was reported earlier that the pGP3 plasmid protein exists in trimeric or 
dimeric form
69
, the gel samples containing the band recognized by the infected mouse sera 
were subjected to further analysis. The result of the LC-MS/MS showed that the protein 
which was reacted with the sera of C. muridarum-infected BALB/c mice was the trimeric (84 
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kDa) form of pGP3 (App. III. Fig. 4B). The sera of C. muridarum-infected C57BL/6N mice 
did not show any reactivity with the trimeric form of pGP3 (App. III. Fig. 3B). 
 
 
Re-infection with C. muridarum induced the production of pGP3-specific cellular immune 
response in both mouse strains 
For comparison and quantitation of pGP3- and pGP4-specific T cell reactivity following 
C. muridarum infection in the two mouse strains, spleen cells isolated from C. muridarum re-
infected mice were in vitro re-stimulated with recombinant pGP3 or pGP4 protein, purified 
heat-inactivated C. muridarum EBs, or the similarly treated mock preparation; the 
proliferative responses of the re-stimulated spleen cells were detected after incubation for 3 
days. Uninfected mice served as controls.  
Spleen cells isolated from triple C. muridarum-infected C57BL/6N mice reacted with 
pGP3 after in vitro re-stimulation. In addition, spleen cells of C57BL/6N mice also responded 
with proliferation to pGP4 (Fig. 10A). The spleen cells of C. muridarum-infected BALB/c 
mice did not show reactivity to the recombinant pGP4 protein after in vitro re-stimulation, but 
they recognized and responded with proliferation to the pGP3 protein (Fig. 10B). 
Lymphocytes of both mouse strains showed proliferation after re-stimulation with heat-
inactivated C. muridarum EBs. 
Fig. 10 pGP3- and pGP4-specific cellular immune response in triply C. muridarum-infected C57BL/6N mice 
(A) and BALB/c mice (B), as tested in MTT test. Spleen cells of mice were re-stimulated in vitro with 
recombinant pGP3 or pGP4 protein; heat-inactivated C. muridarum EBs or mock antigens. Uninfected mice 
served as controls. The data are the means ± SD of the SIs of triplicate assays (*p<0.05). 
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Discussion 
 
Aim 1. Members of the IL-17 cytokine family can aggravate the pathology of 
autoimmune and allergic diseases, but they have a beneficial role during infection caused by 
different pathogens
33
. We have demonstrated here that C. pneumoniae induced the expression 
of IL-17A and IL-17F mRNA in BALB/c mice, with peak levels on day 7 and day 4, 
respectively, whereas the expression of IL-17C, IL-17D and IL-17E mRNA did not change 
after a single infection with the pathogen. The expression of IL-23 mRNA, which expands 
and stabilizes Th17 cells to produce IL-17A and IL-17F, preceded the production of IL-17A.  
The involvement of IL-17A in protective immunity against intracellular pathogens such 
as C. pneumoniae is rather controversial. In the event of mycobacterial infection, IL-17A 
exerts an impact on inflammation and the formation of granulomas, but it is not required for 
overall protection
70,71
. Differences in the role of IL-17A have been observed for different 
Salmonella species: IL-17A is not required for the protection against S. enterica, but the 
depletion of Th17 cells in the intestines dramatically increases the frequency of bacteraemia 
in the case of S. Typhimurium infection in monkeys infected with simian immunodeficiency 
virus
72,73
. IL-17A is important in protective immunity at an early stage of infection with 
Listeria monocytogenes in the liver because IL-17A-deficient mice exhibited a reduced 
protective response
74
. The over-expression of IL-17A after a challenge with Klebsiella 
pneumoniae resulted in the local induction of TNF-, IL-1 and MIP-2, augmented 
polymorphonuclear leukocyte recruitment, and enhanced bacterial clearance and survival
75
. 
IL-17A promotes neutrophilic inflammation through the induction of KC, LIX and MIP-2 
production by a variety of target cells
27
. We found that the quantities of KC and MIP-2 in the 
anti-IL-17A antibody-treated mice were reduced 4 days after C. pneumoniae infection. 
Moreover, the neutralization of IL-17A significantly reduced the number of neutrophil 
granulocytes in the BAL fluid relative to that for the isotype antibody-treated mice. The in 
vivo neutralization of IL-17A resulted in an increased pathogen burden at an early stage of 
infection; the amount of recoverable C. pneumoniae was increased 3-fold as compared with 
the isotype-treated controls, suggesting that the decreased release of KC and MIP-2 in 
response to anti-IL-17A treatment was associated with decreased lung neutrophil recruitment 
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and attenuated bacterial clearance. Based on these results we assumed that IL-17A exerts an 
indirect antimicrobial effect during C. pneumoniae infection. A similar antibacterial effect of 
IL-17A was seen in the case of extracellular K. pneumoniae
75
. It has recently been reported 
that IL-17A does not exert a direct antimicrobial effect, because it does not affect the growth 
of either C. muridarum or C. trachomatis L2 in the L-929 cell line
76
.  
As revealed by ELISPOT, the main source of the IL-17A after C. pneumoniae infection 
in BALB/c mice is the CD4
+
 cells. Although, most of the recent studies focused on IL-17A 
produced by CD4
+
 Th 17 cells,  T cells are potent contributors to the immune responses 
following infections by intracellular pathogens, such as L. monocytogenes, Mycobacterium 
tuberculosis and M. bovis
74,77,78
. Moreover, other cell types, e.g. CD8
+
 T cells and NK cells 
have been demonstrated to be IL-17A-producing cells
79
. In our experiments the depletion of 
CD8
+
 cells did not influence the number of IL-17A-producing cells in the ELISPOT assay.  
Immunopathological mechanisms of chlamydial infections have been widely studied by 
using animal models of repeated infections. Multiple episodes of re-infections with C. 
trachomatis elicit some protective immunity, but the limited growth of chlamydia induces a 
severe inﬂammation that may lead to irreversible tissue changes21. Moreover, a primary C. 
pneumoniae infection conferred a partial resistance to re-infection in a mouse model, but 
provided no protection against inﬂammatory changes, as an equally strong inﬂammatory 
response was observed after re-infection
80
. Our mouse model of repeated infections revealed 
that the re-infection increased the expression of IL-17A and IL-17E mRNA in the lungs of 
mice relative to that in mice infected only once. The production of both cytokine was still 
elevated when viable C. pneumoniae was not present in the lungs, suggesting a role of IL-17A 
and IL-17E in the chronic inflammatory process. Our results suggest that in recurrent 
chlamydial infections the synthesis and release of chlamydial antigens from repeatedly 
infected mucosal epithelial cells or alveolar macrophages may provide a prolonged antigenic 
stimulation, which strongly ampliﬁes chronic inﬂammation. This is an interesting finding in 
the light of the reported putative role of respiratory pathogens such as Chlamydia and 
Mycoplasma in the activation of asthma
81
. On the basis of our results, viable pathogen is 
needed for the expression of IL-17E mRNA, because there was no increase in IL-17E mRNA 
expression after the infection and re-infection of the mice with heat-inactivated C. 
pneumoniae, not even when the mice were inoculated with viable C. pneumoniae first and 
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subsequently treated twice with killed C. pneumoniae. The pattern of expression of IL-17A 
mRNA was different from that of IL-17E mRNA. We observed an increased expression of IL-
17A mRNA in the lungs of mice infected first with viable C. pneumoniae and then twice with 
heat-treated C. pneumoniae.  
We demonstrated that infection with another member of the Chlamydiaceae family – 
with C. muridarum, which belongs not in the Chlamydophila, but in the Chlamydia genus – 
can also induce the production of IL-17A and IL-17E in BALB/c mice. The kinetics of IL-
17A mRNA expression in our experiment was similar to that observed by Zhou et al. after a 
single infection with C. muridarum
82
. Concordant with our earlier results regarded to the re-
infection of mice with C. pneumoniae, the quantity of IL-17E increased four weeks after C. 
muridarum-infection and re-infection. It is noteworthy that the re-infection of mice with C. 
muridarum resulted in acutely decreased levels of expression and production of IL-17E. We 
speculate that the strong Th1 cytokine IFN- can inhibit the expression of IL-17E during the 
early stages of C. muridarum infection.  
It was reported earlier that the production of IL-17E by T cells, mast cells and other 
haematopoietic immune cells is not essential for the development of Th2-type/eosinophilic 
airway inflammation, suggesting that the IL-17E produced by non-immune cells such as 
airway epithelial cells, is crucial for its development
83
. We found that the epithelial cells of 
the lung are responsible for the production of IL-17E in the later stages of pulmonary C. 
muridarum infection.  
Aim 2. The cryptic plasmid of chlamydiae is considered to be a virulence factor, because 
plasmid-free variants have been found to be less invasive and to cause pathologies of 
relatively low severity
53
. Loss of the plasmid from C. muridarum impacts two virulence-
associated phenotypes, infectivity and TLR2 activation, and also the ability of chlamydiae to 
accumulate glycogen
84
. The kinetics of the expression of plasmid genes has not been 
examined earlier in different mouse strains.  
Our experimental findings confirmed the results of Jiang et al. that the chlamydia burden 
is higher in BALB/c mice than in C57BL/6N mice
85
. In C57BL/6N mice, the expression of 
the plasmid genes was not increased in the early phase of the infection, but by day 14 it was 
more pronounced than in the BALB/c strain. The expression levels of the plasmid genes in the 
BALB/c mice rather followed the kinetics of the pathogen burden. A further interesting 
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finding was that the levels of expression of TCA04 and TCA05, which encode pGP3 and 
pGP4, respectively, were uniformly elevated 3-fold in the BALB/c mice on day 7 and day 14 
suggesting that these 2 genes are closely related, or interdependent. It was very recently 
reported by Song et al. that pGP4 is the gene that regulates the transcription of plasmid- 
encoded pGP3 and multiple chromosomal genes during Chlamydia trachomatis infection
57
. 
Moreover, a sequence of 30 or more nucleotides in the pGP3 gene was required for the 
optimal expression of pGP4
86
. 
Aim 3. Our Western blot experiment showed that the sera of C. muridarum-infected 
C57BL/6N mice reacted with the monomeric form of pGP3 (28k Da). Moreover, the sera of 
the mice infected 3 times with C. muridarum reacted with the recombinant pGP4 protein. In 
contrast, the sera of multiply C. muridarum-infected BALB/c mice did not recognize the 
monomeric form of pGP3 in Western blot assays, but the sera did react with a protein band 
with higher molecular weight (80-85 kDa). Since the pGP3 plasmid protein has been reported 
to exist in trimeric form, the sample corresponding to the recognized 80-85 kDa protein was 
subjected to further analysis. The results of the LC-MS/MS analysis clearly demonstrated that 
the protein recognized by the sera of the C. muridarum-infected BALB/c mice was the 
trimeric form of pGP3. Li et al. demonstrated that the trimeric form of pGP3 is secreted into 
the host cell cytosol, and their results indicated that human antibodies recognized trimeric, but 
not monomeric pGP3, suggesting that pGP3 is presented to the human immune system as the 
trimer during C. trachomatis urogenital infection
60
. However, others have found that 
seropositive human sera react with the monomeric form of pGP3 in the Western blot assay
87
. 
Moreover, we detected strong monomeric pGP3-specific antibody production after a single 
inoculation with C. muridarum in C57BL/6N mice. Our results lead us to suppose that the 
genetic background of the host can determine whether the monomeric or the trimeric pGP3 is 
recognized.  
The finding that the sera of triply C. muridarum-infected mice recognized the pGP4 
protein suggests that re-infection leads to the increased pGP4-specific antibody production 
which was detected in our Western blot assay after the third infection. Moreover, an 
increasing pGP4-specific humoral immune response was observed not only in the pooled sera 
of mice, but in each individual mouse serum, suggesting that the processes of presentation and 
recognition of the pGP4 epitopes are similar in each C57BL/6N mouse.  
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Furthermore, we described for the first time that the infection of mice with C. muridarum 
can elicit a cellular immune response to plasmid proteins. We observed that the SIs of spleen 
cells collected from multiply C. muridarum-infected C57BL/6N mice were significantly 
higher after in vitro re-stimulation with pGP3 or pGP4 than the SIs of the lymphocytes of 
uninfected mice. The spleen cells of C. muridarum-infected BALB/c mice did not respond 
with proliferation to the recombinant pGP4 protein, but they were able to respond with 
proliferation to the pGP3 antigen after in vitro re-stimulation for 3 days. Further experiments 
are needed to clarify the roles of pGP3 and pGP4 in the initiation of the cellular and humoral 
immune responses of the host in different mouse strains. 
 
 
The following of our results are considered novel 
 
 
 C. pneumoniae infection induces the expression of IL-17A and IL-17F mRNA in the 
lungs of BALB/c mice  
 C. pneumoniae re-infection triggers the production of IL-17A and IL-17E in BALB/c 
mice 
 C. muridarum infection and re-infection induce the expression of IL-17A and IL-17E 
mRNA in the lungs of BALB/c mice 
 The epithelial cells of the lung are responsible for the production of IL-17E after C. 
muridarum infection and re-infection in BALB/c mice 
 The pMoPn genes display divergent transcriptional pattern in BALB/c mice and in 
C57BL/6N mice  
 Infection with C. muridarum induces the production of pGP3-specific antibodies in 
both mouse strains, but the recognition of pGP3 is dependent on the native 
conformation of the protein 
 Re-infection with C. muridarum induces the pGP4-specific humoral and cellular 
immune responses in C57BL/6N mice but not in BALB/c mice  
 Re-infection with C. muridarum induces the production of pGP3-specific cellular 
immune response in both mouse strains 
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Summary 
Chlamydiae are obligate intracellular bacteria that cause infections which are common 
throughout the world. Chlamydophila pneumoniae is an important respiratory tract pathogen; 
it causes community-acquired pneumonia, bronchitis and sinusitis. Different serovariants of 
Chlamydia trachomatis cause a wide range of diseases, including blinding trachoma, 
urogenital tract infections leading to urethritis, cervicitis and proctitis, and systemic 
lymphogranuloma venereum disease. Although antibiotics are effective in treating chlamydial 
infections, the lack of obvious symptoms has the consequence that many infections remain 
untreated potentially leading to complications characterised by inflammatory pathologies. The 
immunity to these pathogens is not effective, chlamydial infections display high rates of 
recurrence and have long-term consequences causing a serious public health problem. 
Understanding the immunological basis of immunity to chlamydiae will provide an 
indispensable knowledge for the design of a vaccine against diseases caused by these 
pathogens.  
Several Chlamydia species harbour a cryptic plasmid, but the roles of the plasmid-
encoded or regulated proteins in either chlamydial pathogenesis or protective immunity 
remain largely unknown. Growing evidence indicates that the immune responses mediated by 
different IL-17 cytokines play a critical role in the protective mechanisms against bacterial 
and fungal infections, and in the development of allergic and autoimmune diseases.  
The present study was designated to improve our current understanding of the 
pathological immune response to infection and re-infection with chlamydiae, and to provide 
information about the host immune responses against the different chlamydial plasmid 
proteins.  
We have demonstrated that infection with C. pneumoniae induced the expression of IL-
17A and IL-17F mRNA in BALB/c mice, whereas the expression of IL-17C, IL-17D and IL-
17E mRNA did not change after a single infection with the pathogen. The in vivo 
neutralization of IL-17A significantly reduced the number of neutrophil granulocytes and 
increased the pathogen burden in the lungs of C. pneumoniae-infected mice. We have 
revealed that the main source of the IL-17A after C. pneumoniae infection in BALB/c mice is 
the CD4
+
 cells.  
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Our mouse model of repeated infections revealed that re-infection increased the 
expression of IL-17A and IL-17E mRNA in the lungs of mice relative to that in mice infected 
only once. Infection with C. muridarum can also induce the production of IL-17A and IL-17E 
in BALB/c mice. The production of both cytokines was still elevated when viable chlamydiae 
were not present in the lungs, suggesting a role of IL-17A and IL-17E in the chronic 
inflammatory process.  
Infection of BALB/c and C57BL/6N mice with C. muridarum revealed that BALB/c 
mice are more susceptible to C. muridarum infection than C57BL/6N mice. The chlamydial 
plasmid genes displayed divergent transcriptional pattern in BALB/c and in C57BL/6N mice, 
and the immune response to pGP3 and pGP4 plasmid proteins was also different in the two 
mouse strains. The sera of C. muridarum-infected C57BL/6N mice reacted with the 
monomeric form of pGP3 in Western blot assay. In contrast, the sera of multiple-infected 
BALB/c mice did not recognize the monomeric form of pGP3, but the sera did react with an 
additional protein band which was proved to be the trimeric form of pGP3. These results 
suggest that recognition of pGP3 is dependent on the native conformation of the protein, and 
the genetic background of the host can determine whether the monomeric or the trimeric form 
is recognized. Triple infection with C. muridarum elicited pGP4-specific humoral immune 
response in C57BL/6N, but not in BALB/c mice. Spleen cells isolated from C. muridarum-
infected C57BL/6N mice reacted with proliferation after in vitro re-stimulation with pGP3 
and pGP4. The spleen cells of C. muridarum-infected BALB/c mice did not show reactivity to 
the recombinant pGP4 protein after in vitro re-stimulation, but they responded with 
proliferation to the pGP3 protein.  
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Összefoglalás 
A Chlamydiaceae család tagjai obligát intracelluláris baktériumok, melyek által okozott 
betegségek az egész világon elterjedtek. A Chlamydophila pneumoniae egy jelentős légúti 
patogén, a közösségben szerzett tüdőgyulladás, a bronchitis és a sinusitis gyakori kórokozója. 
A Chlamydia trachomatis szerovariánsok különböző betegségeket okoznak, többek között a 
trachomát, urogenitális traktus fertőzéseit (urethritis, cervicitis, proctitis) és a szisztémás 
lymphogranuloma venereumot. Az antibiotikumok hatásosak ugyan a chlamydia fertőzések 
kezelésében, de a jellegzetes tünetek gyakori hiánya miatt a fertőzések legtöbbször 
kezeletlenek maradnak, mely komoly gyulladásos szövődmények kialakulásához vezethet. A 
chlamydiák ellen kialakult immunológiai védelem nem maradandó, ezért gyakoriak a 
visszatérő fertőzések, melyeknek a hosszú távú következményei jelentős közegészségügyi 
problémát jelentenek. Ennek megoldására a leghatékonyabb módszer egy vakcina 
kifejlesztése lenne, melyhez nélkülözhetetlen a chlamydiák ellen kialakult immunválasz 
részletes megismerése.  
Néhány chlamydia faj hordoz egy plazmidot, mely fontos virulencia faktor, azonban a 
plazmidon kódolt fehérjék szerepe a fertőzések pathomechanizmusában ill. a chlamydiák által 
kiváltott immunválaszban még nem teljesen tisztázott. Az immunrendszer baktériumok és 
gombák ellen irányuló védelmében egyre nagyobb jelentőséget tulajdonítanak a különböző 
IL-17 citokinek által mediált immunfolyamatoknak, melyek fontos szerepet játszanak az 
allergiás és az autoimmun betegségek kialakulásában is.  
A kutatásunk célja a chlamydia fertőzések által indukált gyulladásos 
immunfolyamatokról megszerzett ismereteink további bővítése, továbbá a plazmidon kódolt 
fehérjékre kialakult immunválasz vizsgálata a fertőzés során.  
 Kísérleteink során kimutattuk, hogy a C. pneumoniae-vel való fertőzés indukálja a 
BALB/c egerekben az IL-17A és IL-17F mRNS kifejeződését, miközben az IL-17C, IL-17D 
és IL-17E mRNS szintje egyszeri fertőzés hatására nem változik. Az IL-17A in vivo 
neutralizációja szignifikánsan csökkenti a neutrophil granulocyták számát és növeli a 
visszatenyészthető chlamydia mennyiségét a C. pneumoniae-vel fertőzött egerek tüdejében. 
Bebizonyítottuk, hogy BALB/c egerek C. pneumoniae fertőzése során a CD4+ sejtek a 
felelősek az IL-17A termeléséért.  
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Az ismételt chlamydia fertőzések gyulladásra gyakorolt hatásának vizsgálata során 
kimutattunk, hogy az IL-17A és az IL-17E mRNS mennyisége a reinfekciók hatására 
jelentősen megemelkedik az egerek tüdejében az első fertőzés után mérthez képest. A fertőzés 
késői szakaszában, amikor már élő kórokozót nem tudtunk kimutatni az egerek tüdejéből, 
mindkét citokin szintje jelentősen megemelkedett, mely felveti annak lehetőségét, hogy az IL-
17A és IL-17E szerepet játszik a krónikus gyulladásos folyamatokban.  
A C. trachomatis modelljeként használt egérpatogén C. muridarum-mal végzett 
kísérleteink alapján elmondhatjuk, hogy a BALB/c egerek sokkal érzékenyebbek C. 
muridarum-mal szemben, mint a C57BL/6N egerek. A plazmid gének kifejeződési mintázata 
eltérő a két egértörzsben és emellett két plazmidfehérjére, a pGP3-ra és a pGP4-re kialakult 
immunválasz is különbözik.  Western blot során a C. muridarum-mal fertőzött C57BL/6N 
egerek széruma felismeri a monomer pGP3 fehérjét. Ezzel szemben a többször C. muridarum-
mal fertőzött BALB/c egerek széruma nem reagál a pGP3 monomerjével, de felismer egy 
másik fehérjét, melyről további vizsgálat során bebizonyosodott, hogy a pGP3 trimer formája. 
Ezek az eredmények arra utalnak, hogy a pGP3 felismerése függ a fehérje natív 
konformációjától és a gazdaszervezet genetikai hátterétől. A többszöri C. muridarum fertőzés 
csak a C57BL/6N egerekben indukálja a pGP4 specifikus immunválasz kialakulását. Az in 
vitro restimulációt követően a C. muridarum-mal fertőzött C57BL/6N egerek lépsejtjei 
reagáltak mind a pGP3, mind pGP4 fehérjékre, míg a C. muridarum-mal fertőzött BALB/c 
egerek lépsejtjei nem ismerték fel a pGP4-et, de a pGP3 fehérjére proliferációval válaszoltak.  
 
 46 
Acknowledgements 
I would like to express my sincere and ever-lasting gratitude to my supervisor Dr. 
Katalin Burián for introducing me to scientific research. I would like to thank her for 
continuous support, never-failing interest and her encouragement.  
I greatly acknowledge Professor Yvette Mándi, Head of the Doctoral School of 
Interdisciplinary Medicine and former Head of the Department of Medical Microbiology and 
Immunobiology for providing working facilities.  
I would like to thank to Dr. Valéria Endrész for supporting me in both professional and 
human aspects. 
I thank to Mrs Lévai and Mrs Müller for their excellent technical assistance and advice. 
I wish to thank to my fellow Ph.D. students for creating a great atmosphere at work and 
nice times during coffee breaks. 
Colleagues and staff members at the Department of Medical Microbiology and 
Immunobiology are gratefully thanked for creating a supportive and pleasant environment. 
I deeply thank my Family for the continuous encouragement, even though they have no 
idea what I am doing at work. 
I express my deepest thanks to my true and only Love who have always supported, 
encouraged and believed in me.  
I dedicate my thesis to my Mother and my Grandmother. 
 
This work was supported by OTKA National Research Fund Grant PD 100442, and Grant 
TÁMOP-4.2.2.A-11-1-KONV-2012-0035  
 47 
References 
1. Everett, K. D., Bush, R. M. & Andersen, A. A. Emended description of the order 
Chlamydiales, proposal of Parachlamydiaceae fam. nov. and Simkaniaceae fam. nov., 
each containing one monotypic genus, revised taxonomy of the family Chlamydiaceae, 
including a new genus and five new species, and standards for the identification of 
organisms. Int J Syst Bacteriol 49 Pt 2, 415–40 (1999). 
2. Bastidas, R. J., Elwell, C. A., Engel, J. N. & Valdivia, R. H. Chlamydial intracellular 
survival strategies. Cold Spring Harb Perspect Med 3, a010256 (2013). 
3. Schoborg, R. V. Chlamydia persistence – a tool to dissect chlamydia–host interactions. 
Microbes Infect. 13, 649–662 (2011). 
4. Hogan, R. J., Mathews, S. A., Mukhopadhyay, S., Summersgill, J. T. & Timms, P. 
Chlamydial Persistence: beyond the Biphasic Paradigm. Infect. Immun. 72, 1843–1855 
(2004). 
5. Grayston, J. T. Background and Current Knowledge of Chlamydia pneumoniae and 
Atherosclerosis. J. Infect. Dis. 181, S402–S410 (2000). 
6. Saikku, P. et al. Serological evidence of an association of a novel Chlamydia, TWAR, 
with chronic coronary heart disease and acute myocardial infarction. Lancet 2, 983–986 
(1988). 
7. Hahn, D. L., Dodge, R. W. & Golubjatnikov, R. Association of Chlamydia pneumoniae 
(strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. 
JAMA J. Am. Med. Assoc. 266, 225–230 (1991). 
8. Burian, K. et al. Independent and joint effects of antibodies to human heat-shock protein 
60 and Chlamydia pneumoniae infection in the development of coronary atherosclerosis. 
Circulation 103, 1503–1508 (2001). 
9. Dreses-Werringloer, U. et al. Initial characterization of Chlamydophila (Chlamydia) 
pneumoniae cultured from the late-onset Alzheimer brain. Int. J. Med. Microbiol. 299, 
187–201 (2009). 
10. Carter, J. D. & Hudson, A. P. The evolving story of Chlamydia-induced reactive arthritis. 
Curr. Opin. Rheumatol. 22, 424–430 (2010). 
 48 
11. Zhan, P. et al. Chlamydia pneumoniae infection and lung cancer risk: A meta-analysis. 
Eur. J. Cancer 47, 742–747 (2011). 
12. Akira, S. & Takeda, K. Toll-like receptor signalling. Nat. Rev. Immunol. 4, 499–511 
(2004). 
13. Prebeck, S. et al. Predominant role of toll-like receptor 2 versus 4 in Chlamydia 
pneumoniae-induced activation of dendritic cells. J. Immunol. Baltim. Md 1950 167, 
3316–3323 (2001). 
14. Yang, Z. P., Kuo, C. C. & Grayston, J. T. A mouse model of Chlamydia pneumoniae 
strain TWAR pneumonitis. Infect. Immun. 61, 2037–2040 (1993). 
15. Cole, A. M. et al. Cutting edge: IFN-inducible ELR- CXC chemokines display defensin-
like antimicrobial activity. J. Immunol. Baltim. Md 1950 167, 623–627 (2001). 
16. Balogh, E. P., Faludi, I., Virók, D. P., Endrész, V. & Burián, K. Chlamydophila 
pneumoniae induces production of the defensin-like MIG/CXCL9, which has in vitro 
antichlamydial activity. Int. J. Med. Microbiol. 301, 252–259 (2011). 
17. Stockinger, B., Bourgeois, C. & Kassiotis, G. CD4+ memory T cells: functional 
differentiation and homeostasis. Immunol. Rev. 211, 39–48 (2006). 
18. Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A. & Coffman, R. L. Two 
types of murine helper T cell clone. I. Definition according to profiles of lymphokine 
activities and secreted proteins. J Immunol 136, 2348–57 (1986). 
19. Zhu, J., Yamane, H. & Paul, W. E. Differentiation of effector CD4 T cell populations (*). 
Annu. Rev. Immunol. 28, 445–489 (2010). 
20. Beckett, E. L. et al. TLR2, but Not TLR4, Is Required for Effective Host Defence against 
Chlamydia Respiratory Tract Infection in Early Life. PLoS ONE 7, e39460 (2012). 
21. Morrison, R. P. Chlamydial hsp60 and the immunopathogenesis of chlamydial disease. 
Semin Immunol 3, 25–33 (1991). 
22. Ordoñez, C. L., Shaughnessy, T. E., Matthay, M. A. & Fahy, J. V. Increased neutrophil 
numbers and IL-8 levels in airway secretions in acute severe asthma: Clinical and biologic 
significance. Am. J. Respir. Crit. Care Med. 161, 1185–1190 (2000). 
23. McGeachy, M. J. & Cua, D. J. Th17 cell differentiation: the long and winding road. 
Immunity 28, 445–53 (2008). 
 49 
24. Korn, T., Bettelli, E., Oukka, M. & Kuchroo, V. K. IL-17 and Th17 Cells. Annu. Rev. 
Immunol. 27, 485–517 (2009). 
25. Wu, C. et al. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. 
Nature 496, 513–517 (2013). 
26. Reynolds, J. M., Angkasekwinai, P. & Dong, C. IL-17 family member cytokines: 
regulation and function in innate immunity. Cytokine Growth Factor Rev 21, 413–23 
(2010). 
27. Happel, K. I. et al. Divergent roles of IL-23 and IL-12 in host defense against Klebsiella 
pneumoniae. J Exp Med 202, 761–9 (2005). 
28. Carlson, T., Kroenke, M., Rao, P., Lane, T. E. & Segal, B. The Th17-ELR+ CXC 
chemokine pathway is essential for the development of central nervous system 
autoimmune disease. J. Exp. Med. 205, 811–823 (2008). 
29. Sarkar, S., Cooney, L. A. & Fox, D. A. The role of T helper type 17 cells in inflammatory 
arthritis. Clin. Exp. Immunol. 159, 225–237 (2010). 
30. Vincent, F. B., Northcott, M., Hoi, A., Mackay, F. & Morand, E. F. Clinical associations 
of serum interleukin-17 in systemic lupus erythematosus. Arthritis Res. Ther. 15, R97 
(2013). 
31. Sugihara, T. et al. The increased mucosal mRNA expressions of complement C3 and 
interleukin-17 in inflammatory bowel disease: Complement synthesis and Il-17. Clin. 
Exp. Immunol. 160, 386–393 (2010). 
32. Martin, D. A. et al. The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: 
Preclinical and Clinical Findings. J. Invest. Dermatol. 133, 17–26 (2013). 
33. Iwakura, Y., Ishigame, H., Saijo, S. & Nakae, S. Functional specialization of interleukin-
17 family members. Immunity 34, 149–62 (2011). 
34. Angkasekwinai, P. et al. Interleukin 25 promotes the initiation of proallergic type 2 
responses. J. Exp. Med. 204, 1509–1517 (2007). 
35. Stephens, R. S. Chlamydia: intracellular biology, pathogenesis, and immunity. (ASM 
Press, 1999). 
36. Bébéar, C. & de Barbeyrac, B. Genital Chlamydia trachomatis infections. Clin Microbiol 
Infect 15, 4–10 (2009). 
 50 
37. Barron, A. L., White, H. J., Rank, R. G., Soloff, B. L. & Moses, E. B. A new animal 
model for the study of Chlamydia trachomatis genital infections: infection of mice with 
the agent of mouse pneumonitis. J. Infect. Dis. 143, 63–66 (1981). 
38. Stephens, R. S. et al. Genome sequence of an obligate intracellular pathogen of humans: 
Chlamydia trachomatis. Science 282, 754–759 (1998). 
39. Morrison, R. P. & Caldwell, H. D. Immunity to Murine Chlamydial Genital Infection. 
Infect. Immun. 70, 2741–2751 (2002). 
40. Brunham, R. C. & Rey-Ladino, J. Immunology of Chlamydia infection: implications for a 
Chlamydia trachomatis vaccine. Nat. Rev. Immunol. 5, 149–161 (2005). 
41. Conway, D. J. et al. Scarring trachoma is associated with polymorphism in the tumor 
necrosis factor alpha (TNF-alpha) gene promoter and with elevated TNF-alpha levels in 
tear fluid. Infect Immun 65, 1003–6 (1997). 
42. Geisler, W. M., Tang, J., Wang, C., Wilson, C. M. & Kaslow, R. A. Epidemiological and 
genetic correlates of incident Chlamydia trachomatis infection in North American 
adolescents. J Infect Dis 190, 1723–9 (2004). 
43. Rupp, J. et al. CD14 promoter polymorphism -159C>T is associated with susceptibility to 
chronic Chlamydia pneumoniae infection in peripheral blood monocytes. Genes Immun 5, 
435–8 (2004). 
44. Wang, C. et al. Human leukocyte antigen and cytokine gene variants as predictors of 
recurrent Chlamydia trachomatis infection in high-risk adolescents. J Infect Dis 191, 
1084–92 (2005). 
45. Qiu, H. et al. Less inhibition of interferon-gamma to organism growth in host cells may 
contribute to the high susceptibility of C3H mice to Chlamydia trachomatis lung 
infection. Immunology 111, 453–61 (2004). 
46. Qiu, H. et al. Resistance to chlamydial lung infection is dependent on major 
histocompatibility complex as well as non-major histocompatibility complex 
determinants. Immunology 116, 499–506 (2005). 
47. Yang, X., HayGlass, K. T. & Brunham, R. C. Genetically determined differences in IL-10 
and IFN-gamma responses correlate with clearance of Chlamydia trachomatis mouse 
pneumonitis infection. J Immunol 156, 4338–44 (1996). 
 51 
48. Williams, D. R. & Thomas, C. M. Active partitioning of bacterial plasmids. J. Gen. 
Microbiol. 138, 1–16 (1992). 
49. Thomas, N. S., Lusher, M., Storey, C. C. & Clarke, I. N. Plasmid diversity in Chlamydia. 
Microbiology 143 ( Pt 6), 1847–54 (1997). 
50. Read, T. D. et al. Genome sequences of Chlamydia trachomatis MoPn and Chlamydia 
pneumoniae AR39. Nucleic Acids Res. 28, 1397–1406 (2000). 
51. Comanducci, M., Ricci, S., Cevenini, R. & Ratti, G. Diversity of the Chlamydia 
trachomatis common plasmid in biovars with different pathogenicity. Plasmid 23, 149–
154 (1990). 
52. Kari, L. et al. A live-attenuated chlamydial vaccine protects against trachoma in 
nonhuman primates. J Exp Med 208, 2217–23 (2011). 
53. O’Connell, C. M., Ingalls, R. R., Andrews, C. W., Scurlock, A. M. & Darville, T. 
Plasmid-deficient Chlamydia muridarum fail to induce immune pathology and protect 
against oviduct disease. J Immunol 179, 4027–34 (2007). 
54. Thomson, N. R. et al. Chlamydia trachomatis: genome sequence analysis of 
lymphogranuloma venereum isolates. Genome Res. 18, 161–171 (2008). 
55. Wang, Y. et al. Development of a transformation system for Chlamydia trachomatis: 
restoration of glycogen biosynthesis by acquisition of a plasmid shuttle vector. PLoS 
Pathog. 7, e1002258 (2011). 
56. Carlson, J. H. et al. The Chlamydia trachomatis plasmid is a transcriptional regulator of 
chromosomal genes and a virulence factor. Infect Immun 76, 2273–83 (2008). 
57. Song, L. et al. Chlamydia trachomatis Plasmid-Encoded Pgp4 Is a Transcriptional 
Regulator of Virulence-Associated Genes. Infect. Immun. 81, 636–644 (2013). 
58. Liu, Y. et al. Transformation of Chlamydia muridarum Reveals a Role for Pgp5 in 
Suppression of Plasmid-Dependent Gene Expression. J. Bacteriol. 196, 989–998 (2013). 
59. O’Connell, C. M. et al. Toll-like receptor 2 activation by Chlamydia trachomatis is 
plasmid dependent, and plasmid-responsive chromosomal loci are coordinately regulated 
in response to glucose limitation by C. trachomatis but not by C. muridarum. Infect. 
Immun. 79, 1044–1056 (2011). 
 52 
60. Li, Z., Chen, D., Zhong, Y., Wang, S. & Zhong, G. The chlamydial plasmid-encoded 
protein pgp3 is secreted into the cytosol of Chlamydia-infected cells. Infect Immun 76, 
3415–28 (2008). 
61. Comanducci, M. et al. Humoral immune response to plasmid protein pgp3 in patients 
with Chlamydia trachomatis infection. Infect. Immun. 62, 5491–5497 (1994). 
62. Chen, D. et al. Characterization of Pgp3, a Chlamydia trachomatis Plasmid-Encoded 
Immunodominant Antigen. J. Bacteriol. 192, 6017–6024 (2010). 
63. Donati, M. et al. DNA immunization with pgp3 gene of Chlamydia trachomatis inhibits 
the spread of chlamydial infection from the lower to the upper genital tract in C3H/HeN 
mice. Vaccine 21, 1089–1093 (2003). 
64. National Center for Biotechnology Information. at <http://www.ncbi.nlm.nih.gov/> 
65. Burián, K. et al. Chlamydophila (Chlamydia) pneumoniae induces histidine 
decarboxylase production in the mouse lung. Immunol Lett 89, 229–36 (2003). 
66. Borges, V. et al. Normalization strategies for real-time expression data in Chlamydia 
trachomatis. J Microbiol Methods 82, 256–64 (2010). 
67. Höner Zu Bentrup, K., Miczak, A., Swenson, D. L. & Russell, D. G. Characterization of 
activity and expression of isocitrate lyase in Mycobacterium avium and Mycobacterium 
tuberculosis. J Bacteriol 181, 7161–7 (1999). 
68. Tabor, S. & Richardson, C. C. A bacteriophage T7 RNA polymerase/promoter system for 
controlled exclusive expression of specific genes. Proc Natl Acad Sci U A 82, 1074–8 
(1985). 
69. Chen, D. et al. Characterization of Pgp3, a Chlamydia trachomatis plasmid-encoded 
immunodominant antigen. J Bacteriol 192, 6017–24 (2010). 
70. Khader, S. A. et al. IL-23 compensates for the absence of IL-12p70 and is essential for 
the IL-17 response during tuberculosis but is dispensable for protection and antigen-
specific IFN-gamma responses if IL-12p70 is available. J Immunol 175, 788–95 (2005). 
71. Okamoto Yoshida, Y. et al. Essential role of IL-17A in the formation of a mycobacterial 
infection-induced granuloma in the lung. J Immunol 184, 4414–22 (2010). 
72. Raffatellu, M. et al. Simian immunodeficiency virus-induced mucosal interleukin-17 
deficiency promotes Salmonella dissemination from the gut. Nat Med 14, 421–8 (2008). 
 53 
73. Schulz, S. M. et al. Protective immunity to systemic infection with attenuated Salmonella 
enterica serovar enteritidis in the absence of IL-12 is associated with IL-23-dependent IL-
22, but not IL-17. J Immunol 181, 7891–901 (2008). 
74. Hamada, S. et al. IL-17A produced by gamma delta T cells plays a critical role in innate 
immunity against Listeria monocytogenes infection in the liver. J. Immunol. 181, 3456–
3463 (2008). 
75. Ye, P. et al. Interleukin-17 and lung host defense against Klebsiella pneumoniae 
infection. Am. J. Respir. Cell Mol. Biol. 25, 335–340 (2001). 
76. Zhang, X. et al. A MyD88-dependent early IL-17 production protects mice against airway 
infection with the obligate intracellular pathogen Chlamydia muridarum. J Immunol 183, 
1291–300 (2009). 
77. Lockhart, E., Green, A. M. & Flynn, J. L. IL-17 production is dominated by gammadelta 
T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol 
177, 4662–9 (2006). 
78. Umemura, M. et al. IL-17-mediated regulation of innate and acquired immune response 
against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J Immunol 
178, 3786–96 (2007). 
79. Cua, D. J. & Tato, C. M. Innate IL-17-producing cells: the sentinels of the immune 
system. Nat Rev Immunol 10, 479–89 (2010). 
80. Kaukoranta-Tolvanen, S. S. et al. Experimental infection of Chlamydia pneumoniae in 
mice. Microb Pathog 15, 293–302 (1993). 
81. Daian, C. M., Wolff, A. H. & Bielory, L. The role of atypical organisms in asthma. 
Allergy Asthma Proc. Off. J. Reg. State Allergy Soc. 21, 107–111 (2000). 
82. Zhou, X. et al. Critical Role of the Interleukin-17/Interleukin-17 Receptor Axis in 
Regulating Host Susceptibility to Respiratory Infection with Chlamydia Species. Infect. 
Immun. 77, 5059–5070 (2009). 
83. Suzukawa, M. et al. Epithelial cell-derived IL-25, but not Th17 cell-derived IL-17 or IL-
17F, is crucial for murine asthma. J Immunol 189, 3641–52 (2012). 
84. O’Connell, C. M. & Nicks, K. M. A plasmid-cured Chlamydia muridarum strain displays 
altered plaque morphology and reduced infectivity in cell culture. Microbiology 152, 
1601–7 (2006). 
 54 
85. Jiang, X., Shen, C., Yu, H., Karunakaran, K. P. & Brunham, R. C. Differences in innate 
immune responses correlate with differences in murine susceptibility to Chlamydia 
muridarum pulmonary infection. Immunology 129, 556–66 (2010). 
86. Gong, S., Yang, Z., Lei, L., Shen, L. & Zhong, G. Characterization of Chlamydia 
trachomatis Plasmid-Encoded Open Reading Frames. J Bacteriol 195, 3819–26 (2013). 
87. Comanducci, M. et al. Expression of a plasmid gene of Chlamydia trachomatis encoding 
a novel 28 kDa antigen. J Gen Microbiol 139, 1083–92 (1993). 
 55 
Appendix 
